We are live on ! Find out more
IGC icon

IGC Pharma
IGC

6 hedge funds and large institutions have $37K invested in IGC Pharma in 2014 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

20% more funds holding

Funds holding: 5 → 6 (+1)

3% more capital invested

Capital invested by funds: $36K → $37K (+$1K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$21.6K
2
LTFS
Ladenburg Thalmann Financial Services
Florida
+$1.09K

Top Sellers

Rank Fund Capital Flow
1
Creative Planning
Creative Planning
Kansas
-$20K
2
VKH
Virtu KCG Holdings
New York
-$4.36K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$21K +$21.6K +29,804 New
VKH
2
Virtu KCG Holdings
New York
$9K -$4.36K -6,025 -30%
UBS Group
3
UBS Group
Switzerland
$5K +$5.1K +7,048 New
VIA
4
Vantage Investment Advisors
Pennsylvania
$1K – – –
LTFS
5
Ladenburg Thalmann Financial Services
Florida
$1K +$1.09K +1,500 New
Creative Planning
6
Creative Planning
Kansas
– -$20K -28,400 Closed

IGC Hedge Fund Activity: Q4 2014 in Review

6 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2014, worth a combined $37K — up 2.8% from $36K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new IGC positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $21.6K. The largest seller was Creative Planning, exiting entirely with an estimated $20K sold.

  • 6 institutional investors held IGC Pharma (IGC) as of Q4 2014, up from 5 in Q3 2014.
  • Funds reported $37K of IGC Pharma stock for Q4 2014, up 2.8% quarter-over-quarter.
  • 3 funds opened new IGC Pharma positions in Q4 2014 and 1 closed out, a net change of +2 holders.
  • The largest IGC Pharma buyer in Q4 2014 was Citadel Advisors, an estimated $21.6K added.
  • The largest IGC Pharma seller in Q4 2014 was Creative Planning, an estimated $20K sold.

Based on aggregated 13F filings for Q4 2014.